Back to Search
Start Over
Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
- Source :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(5)
- Publication Year :
- 2020
-
Abstract
- Introduction Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from non-small cell lung cancer. Methods Tyrosine kinase inhibitor adherence was measured electronically by MEMS® (medication event monitoring system) over at least six months. Adherence rates were calculated in terms of Dosing Compliance, Timing Compliance, Taking Compliance, and Drug Holidays. Patients were dichotomized as adherent when Dosing Compliance and Timing Compliance were ≥80%, Taking Compliance ranged between 90 and 110%, and Results Out of 32 patients enrolled, data from 23 patients were evaluable. Median Dosing Compliance, Taking Compliance, and Timing Compliance adherence rates of tyrosine kinase inhibitor intake amounted to 100%, 98%, and 99%, respectively; Drug Holidays were observed in three patients. Four patients were dichotomized as non-adherent. Three of them had a twice-daily tyrosine kinase inhibitor regimen. Median quality of life scores amounted to 67 (max. 100) and remained unchanged over the study period. Fatigue and rash were the most frequently reported adverse drug events. Conclusion Medication adherence of non-small cell lung cancer patients treated with tyrosine kinase inhibitors was extraordinarily high and is likely to support the effectiveness of tyrosine kinase inhibitor treatment and a good quality of life over a long period of time. Adherence facilitating information and education is especially relevant for patients taking tyrosine kinase inhibitors in a twice-daily regimen.
- Subjects :
- Oncology
Adult
Male
medicine.medical_specialty
Lung Neoplasms
medicine.drug_class
medicine.medical_treatment
Tyrosine-kinase inhibitor
Medication Adherence
03 medical and health sciences
0302 clinical medicine
Quality of life
Internal medicine
Carcinoma, Non-Small-Cell Lung
medicine
Humans
Pharmacology (medical)
ddc:610
030212 general & internal medicine
Patient Reported Outcome Measures
Prospective Studies
Lung cancer
Adverse effect
Protein Kinase Inhibitors
Aged
Aged, 80 and over
Chemotherapy
business.industry
Cancer
Middle Aged
Protein-Tyrosine Kinases
medicine.disease
030220 oncology & carcinogenesis
Quality of Life
Observational study
Female
business
Tyrosine kinase
Subjects
Details
- ISSN :
- 1477092X
- Volume :
- 27
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Accession number :
- edsair.doi.dedup.....0c87f5425a2f3a782b5a841cab4a97f8